Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
120%(6 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
4
67%
Ph phase_2
2
33%

Phase Distribution

0

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
4(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (33.3%)
Phase 34 (66.7%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

NCT04400058
completedphase_3

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

NCT02728752
completedphase_2

Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease

NCT03319810
terminatedphase_3

Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

NCT00811174
completedphase_3

Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

NCT00426270
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04400058Phase 3

Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

Completed
NCT02728752Phase 3

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

Completed
NCT03319810Phase 2

Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease

Completed
NCT00811174Phase 3

Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

Terminated
NCT00426270Phase 3

Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

Completed
NCT00812565Phase 2

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6